Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Gastric endocrine tumors associated with autoimmune chronic atrophic gastritis (gastric carcinoid type I) are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. For this reason, the role of octreotide in the treatment of these neoplastic lesions is controversial. Nine patients with more than five type I gastric endocrine tumors each <1 cm in size, without invasion of the muscularis propria and with Ki-67 index lower than 3%, were treated with long-acting somatostatin analogs for 12 months. After 6 months and again after 12 months, all the patients underwent upper gastrointestinal (GI) endoscopy with multiple biopsies. The plasma chromogranin A (CgA) levels and the gastrin levels in the serum were also determined. In all patients, the gastric neoplastic lesions disappeared after 12 months of somatostatin analog therapy. We also observed a significant reduction of CgA and gastrin levels at 6 and at 12 months of therapy as compared with the baseline values. We demonstrate that somatostatin analog treatment provokes the pathological regression of type I gastric carcinoids. This therapeutic approach should be considered as a valid option in selected patients with multiple type I gastric endocrine tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and Grading of Gastritis: The Updated Sydney System
Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199610000-00001 · Cited by 5,185
Cited by
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms
Delle Fave, G., Kwekkeboom, D. J., Van Cutsem, E., Rindi, G., Kos-Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., & Ruszniewski, P. (2012) · Neuroendocrinology · doi:10.1159/000335595 · Cited by 327
Self-citationType I gastric carcinoids: a prospective study on endoscopic management and recurrence rate
Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., et al. (2012) · Neuroendocrinology · doi:10.1159/000329043 · Cited by 132
Metadata
- Authors
- Campana, D., Nori, F., Pezzilli, R., Piscitelli, L., Santini, D., Brocchi, E., Corinaldesi, R., & Tomassetti, P.
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2008-03-01
- Volume
- 15
- Issue
- 1
- Pages
- 337-342
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2117796497
- Cited by
- 74
- References
- 1
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. https://app.cochat.ai/papers/10.1677/erc-07-0251
- The paper
- Campana, D., Nori, F., Pezzilli, R., Piscitelli, L., Santini, D., Brocchi, E., Corinaldesi, R., & Tomassetti, P. (2008). Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocrine Related Cancer. https://doi.org/10.1677/erc-07-0251
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.